pathic ALTEs. 4 This is also in line with recent evidence suggesting that both syndromes could be related.
Evaluation of Effectiveness of Mixed Rotavirus Vaccine Course for Rotavirus Gastroenteritis
Two rotavirus vaccines-RotaTeq (RV5; Merck and Company), a 3-dose series, and Rotarix (RV1; GlaxoSmithKline Biologicals), a 2-dose series-are licensed for use in US children. The US Advisory Committee for Immunization Practices (ACIP) recommends that a rotavirus vaccine series be completed with the same product whenever possible but allows for administering mixed vaccine types if a previous dose type is not available or is unknown. 1 In such situations, the ACIP recommends, "If any dose in the series was RV5 or the vaccine product is unknown for any dose in the series, a total of 3 doses of rotavirus vaccine should be administered." 1 However, the effectiveness of a mixed rotavirus vaccine series remains unclear.
We evaluated the postlicensure vaccine effectiveness (VE) of a complete 3-dose course of mixed rotavirus vaccine types according to the ACIP definition and compared these results with published VE results for the same population and time.
Methods | We collected data on children enrolled in the New Vaccine Surveillance Network from pediatric hospitals and emergency departments in Nashville, Tennessee; Rochester, New York; Cincinnati, Ohio; Seattle, Washington; Houston, Texas; Kansas City, Missouri; and Oakland, California. Each child exhibited diarrhea (≥3 episodes within 24 hours) and/or vomiting (≥1 episode within 24 hours) from December 1, 2011, through November 30, 2013. Rotavirus infections were confirmed using enzyme immunoassays and reverse transcriptionpolymerase chain reactions. Approval was obtained from each institutional review board, and written informed consent was obtained from each patient's parent or legal guardian. Further details of these methods were previously published.
2
Verifications of rotavirus vaccination from primary care professionals were supplemented by regional immunization information systems. Among vaccine-eligible children who had reached the maximum ACIP-recommended age for completion of the vaccine series (ie, 8 months and older) 2 and who had complete, valid vaccination data, we compared rotavirus test positivity from 715 children who were unvaccinated with 75 children who had received a mixed, 3-dose course of rota- Results | Of 2425 children who were considered fully vaccinated, 75 (3.1%) had received a complete 3-dose course of mixed rotavirus vaccine types (Figure) . For the 212 patients testpositive for rotavirus, the median (interquartile range) age was 36 (21-63) months and 36 (18-62) months for the 578 patients test-negative for rotavirus; further comparisons between these groups are demonstrated in the Table. Our adjusted VE for a complete mixed rotavirus vaccination course was 80% (95% CI, 51%-92%).
Discussion | A complete 3-dose rotavirus vaccination regimen with mixed RV5 and RV1 vaccines retains a statistically significant level of protection (80%) against rotavirus gastroenteritis that is nearly identical to the level observed for complete, single vaccine-type regimens. Previously published analyses 2 for this same population and time showed a VE of 80% (95% CI, 74%-84%) for a complete 3-dose vaccination with RV5 only and a VE of 80% (95% CI, 68%-88%) for a complete 2-dose vaccination with RV1 only. The National Immunization Survey found that 73% of age-eligible US children were fully vaccinated with rotavirus vaccines in 2013 among an annual birth cohort of approximately 4.6 million participants.
3 If our results can be extrapolated, then roughly 100 000 US children annually would be immunized with mixed rotavirus vaccine types. Even though phase 3 clinical trials did not assess the efficacy of this practice before US licensure, the topic is currently under study in a postlicensure clinical trial 4 and is supported by another recent study, 5 albeit with numbers too small to achieve statistical significance.
Conclusions | Our results provide empirical evidence supporting the US ACIP recommendation, which allows for the completion of a 3-dose rotavirus vaccination series with either of the licensed rotavirus vaccines when necessary. This practice appears to significantly protect vaccinated infants against rotavirus gastroenteritis. 
